We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0G99 market cap is 170.29T. The company's latest EPS is EUR -0.0054 and P/E is -44.44.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 3.82M | 2M | 967k | 442k | 154k |
| Operating Income | -52.17M | -28.62M | -28.5M | -22.95M | -12.11M |
| Net Income | -51.83M | -28.01M | -29.16M | -31.69M | -18.97M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 65.03M | 34.28M | 18.88M | 11.99M | 6.55M |
| Total Liabilities | 11.72M | 9.24M | 19.98M | 16.58M | 19.74M |
| Total Equity | 53.31M | 25.05M | -1.11M | -4.58M | -13.19M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -31.07M | -27.08M | -26.98M | -19.38M | -9.77M |
| Investing | 10.01M | 10.06M | 407k | 111k | 72k |
| Financing | -877k | -931k | 11.78M | 13M | 7.82M |
| Market Cap | 170.29T |
| Price to Earnings Ratio | -44.44 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 480 |
| Price to Book Ratio | -63.51 |
| Dividend Yield | - |
| Shares Outstanding | 3.49B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 48,800.00 |
| 52 Week Low | 48,800.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Oxurion Nv |
| Address |
gaston geenslaan 1 leuven, flemish brabant B-3001 |
| Website | https://www.oxurion.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
